Comparison of Ticagrelor Versus Clopidogrel on Cerebrovascular Microembolic Events and Platelet Inhibition during Transcatheter Aortic Valve Implantation

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3030593 21 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Comparison of Ticagrelor Versus Clopidogrel on Cerebrovascular
Microembolic Events and Platelet Inhibition during Transcatheter Aortic
Valve Implantation
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The impact of the antiplatelet regimen and the extent of associated
platelet inhibition on cerebrovascular microembolic events during
transcatheter aortic valve implantation (TAVI) are unknown. Our aim was
to evaluate the effects of ticagrelor versus clopidogrel and of platelet
inhibition on the number of cerebrovascular microembolic events in
patients undergoing TAVI. Patients scheduled for TAVI were randomized
previous to the procedure to either aspirin and ticagrelor or to aspirin
and clopidogrel. Platelet inhibition was expressed in P2Y12 reaction
units (PRU) and percentage of inhibition. High intensity transient
signals (HITS) were assessed with transcranial Doppler (TCD). Safety
outcomes were recorded according to the VARC-2 definitions. Among 90
patients randomized, 6 had an inadequate TCD signal. The total number of
procedural HITS was lower in the ticagrelor group (416.5 [324.8,
484.2]) (42 patients) than in the clopidogrel group (723.5 [471.5,
875.0]) (42 patients), p <0.001. After adjusting for the duration of the
procedure, diabetes, extra-cardiac arteriopathy, BMI, hypertension,
aortic valve calcium content, procedural ACT, and pre-implantation
balloon valvuloplasty, patients on ticagrelor had on average 256.8 (95%
CI: [-335.7, -176.5]) fewer total procedural HITS than patients on
clopidogrel. Platelet inhibition was greater with ticagrelor 26 [10,
74.5] PRU than with clopidogrel 207.5 (120 to 236.2) PRU, p <0.001, and
correlated significantly with procedural HITS (r = 0.5, p <0.05). In
conclusion, ticagrelor resulted in fewer procedural HITS, compared with
clopidogrel, in patients undergoing TAVI, while achieving greater
platelet inhibition. (c) 2021 Published by Elsevier Inc.
Έτος δημοσίευσης:
2021
Συγγραφείς:
Vavuranakis, Michael A.
Kalantzis, Charalampos
Voudris, Vassilis
and Kosmas, Elias
Kalogeras, Konstantinos
Katsianos, Efstratios
and Oikonomou, Evaggelos
Siasos, Gerasimos
Aznaouridis,
Konstantinos
Toutouzas, Konstantinos
Stasinopoulou, Myrsini and
Tountopoulou, Argyro
Bei, Evangelia
Moldovan, Carmen M. and
Vrachatis, Dimitrios
Iakovou, Ioannis
Papaioannou, Theodore G.
and Tousoulis, Dimitrios
Leucker, Thorsten M.
Vavuranakis,
Manolis
Περιοδικό:
AMERICAN JOURNAL OF CARDIOLOGY
Εκδότης:
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
Τόμος:
154
Σελίδες:
78-85
Επίσημο URL (Εκδότης):
DOI:
10.1016/j.amjcard.2021.05.047
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.